While Vietnam’s drugmakers are heading to develop new products to increase efficiency and sustain sustainable growth, competition from imported drugs is making their road tougher.
Targets being tweaked by prepared pharma 20:53 | 09/06/2021
illustration photo. Source: freepik.com
According to financial statements from Vietnamese pharma titans like DHG Pharmaceutical JSC, Traphaco JSC, and Imexpharm Pharmaceutical JSC (IMP), there were strong rises in both revenues and profit in the first months of 2021.
DHG, the biggest publicly-traded drugmaker, made consolidated revenue of $50 million, up from just over $40 million in the same period last year. Consolidated after-tax profit hit $8.87 million, up 15.24 per cent on-year.
Similarly, Traphaco, the countryâs second-largest publicly-traded drugmaker, saw on-year rises of 20.87 per cent and 34.06 per cent in consolidated revenue and consolidated after-tax profit respectively during the period. IMP, Vietnamâs fourth-biggest, witnessed a 23.1 per cent on-year increase in before-tax profit in the first four months, while its net revenue rose 9 per cent.
Promising figures offering confidence for pharma future 14:00 | 14/01/2021
Vietnamese pharmaceutical giants rushed to new business lines in 2020 to create new motivation for growth amid the ongoing pandemic complications, with some changes bringing about better results.
Clearly in a happy mood, Vu Thi Thuan, chairwoman of the countryâs second-largest publicly-traded drugmaker Traphaco JSC, is looking towards a bright future in 2021 on the back of good performance last year.
Traphaco, which boasts three big shareholders in State Capital Investment Corporation (35.67 per cent), Magbi Fund Ltd. (24.99 per cent), and Super Delta Pte., Ltd. (15.12 per cent), will organise a conference in the next few days to review 2020 operations and discuss the targets for this year.